{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:10:04Z","timestamp":1748736604205,"version":"3.41.0"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,12,30]],"date-time":"2015-12-30T00:00:00Z","timestamp":1451433600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2015,12,30]],"date-time":"2015-12-30T00:00:00Z","timestamp":1451433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1111\/jcpt.12345","type":"journal-article","created":{"date-parts":[[2015,12,30]],"date-time":"2015-12-30T13:01:43Z","timestamp":1451480503000},"page":"97-100","source":"Crossref","is-referenced-by-count":4,"title":["Clinical experience about an unexpected adverse event during nalmefene treatment in two patients with alcohol use disorder"],"prefix":"10.1155","volume":"41","author":[{"given":"G.","family":"Milano","sequence":"first","affiliation":[{"name":"Department of Internal Medicine; Clinical Pharmacology and Toxicology Unit; University of Genoa; Genoa Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Zavan","sequence":"additional","affiliation":[{"name":"Department of Dependence (Ser.T.); ASL-Al; Alessandria Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. M.","family":"Natta","sequence":"additional","affiliation":[{"name":"Neurology Unit; Istituto Clinico \u02bbSalus\u2019; Alessandria Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Martelli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine; Clinical Pharmacology and Toxicology Unit; University of Genoa; Genoa Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Mattioli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine; Clinical Pharmacology and Toxicology Unit; University of Genoa; Genoa Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,12,30]]},"reference":[{"key":"10.1111\/jcpt.12345-BIB0001|jcpt12345-cit-0001","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(09)60746-7","article-title":"Global burden of disease and injury and economic cost attributable to alcohol use and alcohol use disorders","volume":"373","author":"Rehm","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/jcpt.12345-BIB0002|jcpt12345-cit-0002","doi-asserted-by":"crossref","DOI":"10.1596\/0-1952-1606-7","volume-title":"The world health report 2002: reducing risks, promoting healthy life","author":"World Health Organization","year":"2002"},{"key":"10.1111\/jcpt.12345-BIB0003|jcpt12345-cit-0003","first-page":"57","article-title":"The Italian edition of DSM-5","volume":"49","author":"Biondi","year":"2014","journal-title":"Rivista di Psichiatria"},{"key":"10.1111\/jcpt.12345-BIB0004|jcpt12345-cit-0004","unstructured":"World Health Organization Tenth Revision. International Classification of Diseases Geneva, Switzerland 1992"},{"key":"10.1111\/jcpt.12345-BIB0005|jcpt12345-cit-0005","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","edition":"5"},{"key":"10.1111\/jcpt.12345-BIB0006|jcpt12345-cit-0006","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/alcalc\/agn080","article-title":"The alcoholic phenotypes among different multidimensional typologies: similarities and their classification procedures","volume":"44","author":"Pombo","year":"2009","journal-title":"Alcohol Alcohol"},{"key":"10.1111\/jcpt.12345-BIB0007|jcpt12345-cit-0007","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.npp.1300811","article-title":"Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?","volume":"30","author":"Bart","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1111\/jcpt.12345-BIB0008|jcpt12345-cit-0008","unstructured":"Committee for Medicinal Products for Human Use (CHMP) European public assessment report: Nalmefene http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002583\/WC500140326.pdf"},{"key":"10.1111\/jcpt.12345-BIB0009|jcpt12345-cit-0009","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/ajad.12263","article-title":"To reduce or abstain? Substance use goals in the treatment of veterans with substance use disorders and comorbid PTSD","volume":"24","author":"Lozano","year":"2015","journal-title":"Am J Addict"},{"key":"10.1111\/jcpt.12345-BIB0010|jcpt12345-cit-0010","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2015.1015702","article-title":"Acceptability of non-abstinence goals among students enrolled in addiction studies programs across the United States","author":"Davis","year":"2015","journal-title":"Substance Abuse"},{"key":"10.1111\/jcpt.12345-BIB0011|jcpt12345-cit-0011","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.addbeh.2014.10.036","article-title":"Drinking goal choice and outcomes in a Web-based alcohol intervention: results from VetChange","volume":"42","author":"Enggasser","year":"2015","journal-title":"Addictive Behaviour"},{"key":"10.1111\/jcpt.12345-BIB0012|jcpt12345-cit-0012","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jsat.2013.07.005","article-title":"Differences in the acceptability of non-abstinence goals by type of drug among American substance abuse clinicians","volume":"46","author":"Rosenberg","year":"2014","journal-title":"J Subst Abuse Treat"},{"key":"10.1111\/jcpt.12345-BIB0013|jcpt12345-cit-0013","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0740-5472(01)00210-0","article-title":"Reduced-risk drinking as a treatment goal: what clinicians need to know","volume":"22","author":"Ambrogne","year":"2002","journal-title":"J Subst Abuse Treat"},{"key":"10.1111\/jcpt.12345-BIB0014|jcpt12345-cit-0014","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000357865","article-title":"Can alcohol dependent patients adhere to an \u2018as-needed\u2019 medication regimen?","volume":"20","author":"Sinclair","year":"2014","journal-title":"Eur Addict Res"},{"key":"10.1111\/jcpt.12345-BIB0015|jcpt12345-cit-0015","doi-asserted-by":"crossref","first-page":"e005376","DOI":"10.1136\/bmjopen-2014-005376","article-title":"The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high\/very high drinking risk levels: a Markov model","volume":"4","author":"Laram\u00e9e","year":"2014","journal-title":"BMJ Open"},{"key":"10.1111\/jcpt.12345-BIB0016|jcpt12345-cit-0016","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","article-title":"Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene","volume":"73","author":"Mann","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1111\/jcpt.12345-BIB0017|jcpt12345-cit-0017","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.euroneuro.2013.02.006","article-title":"A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence","volume":"23","author":"Gual","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1111\/jcpt.12345-BIB0018|jcpt12345-cit-0018","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0269881114527362","article-title":"Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependance: a 1-year, randomised controlled study","volume":"28","author":"Brink","year":"2014","journal-title":"Journal of Psychopharmacology"},{"key":"10.1111\/jcpt.12345-BIB0019|jcpt12345-cit-0019","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40263-013-0101-y","article-title":"Nalmefene: a review of its use in the treatment of alcohol dependence","volume":"27","author":"Keating","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1111\/jcpt.12345-BIB0020|jcpt12345-cit-0020","unstructured":"World Health Organization (WHO) International guide for monitoring alcohol consumption and related harm. Department of Mental Health and Substance Dependence, Noncommunicable Diseases and Mental Health Cluster http:\/\/apps.who.int\/iris\/bitstream\/10665\/63850\/1\/a58352_PartA.pdf"},{"key":"10.1111\/jcpt.12345-BIB0021|jcpt12345-cit-0021","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0893-133X(00)00195-0","article-title":"Drug addiction, dysregulation of reward, and allostasis","volume":"24","author":"Koob","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1111\/jcpt.12345-BIB0022|jcpt12345-cit-0022","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1038\/nn1105-1442","article-title":"Plasticity of reward neurocircuitry and the \u2018dark side\u2019 of drug addiction","volume":"8","author":"Koob","year":"2005","journal-title":"Nat Neurosci"},{"key":"10.1111\/jcpt.12345-BIB0023|jcpt12345-cit-0023","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1073\/pnas.85.14.5274","article-title":"Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats","volume":"85","author":"Di Chiara","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/jcpt.12345-BIB0024|jcpt12345-cit-0024","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","article-title":"A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence","volume":"56","author":"Mason","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/jcpt.12345-BIB0025|jcpt12345-cit-0025","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1517\/13543784.2010.522990","article-title":"Nalmefene for treatment of alcohol dependence","volume":"19","author":"Soyka","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/jcpt.12345-BIB0026|jcpt12345-cit-0026","doi-asserted-by":"crossref","first-page":"g1531","DOI":"10.1136\/bmj.g1531","article-title":"Bad medicine: nalmefene in alcohol misuse","volume":"348","author":"Spence","year":"2014","journal-title":"Br Med J"},{"key":"10.1111\/jcpt.12345-BIB0027|jcpt12345-cit-0027","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12345-BIB0028|jcpt12345-cit-0028","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.36076\/ppj.2008\/11\/S133","article-title":"Opioid pharmacology","volume":"11","author":"Trescot","year":"2008","journal-title":"Pain Physician"},{"key":"10.1111\/jcpt.12345-BIB0029|jcpt12345-cit-0029","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/sj.npp.1301438","article-title":"Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence","volume":"33","author":"Walker","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1111\/jcpt.12345-BIB0030|jcpt12345-cit-0030","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/YIC.0000000000000069","article-title":"Treatment of cocaine craving with as-needed nalmefene, a partial \u03ba opioid receptor agonist: first clinical experience","volume":"30","author":"Grosshans","year":"2015","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1111\/jcpt.12345-BIB0031|jcpt12345-cit-0031","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1749-6632.1999.tb09286.x","article-title":"D3 dopamine and kappa opioid receptor alterations in human brain of cocaine-overdose victims","volume":"877","author":"Mash","year":"1999","journal-title":"Ann N Y Acad Sci"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12345","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12345","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12345\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T23:46:25Z","timestamp":1748735185000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,30]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12345","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"type":"print","value":"0269-4727"}],"subject":[],"published":{"date-parts":[[2015,12,30]]}}}